BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27874210)

  • 21. Cost-effectiveness of point-of-care C-reactive protein tests for respiratory tract infection in primary care in England.
    Hunter R
    Adv Ther; 2015 Jan; 32(1):69-85. PubMed ID: 25620538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening and case finding tools for the detection of dementia. Part I: evidence-based meta-analysis of multidomain tests.
    Mitchell AJ; Malladi S
    Am J Geriatr Psychiatry; 2010 Sep; 18(9):759-82. PubMed ID: 20808118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cost of diagnosis and early support in patients with cognitive decline.
    Pennington M; Gomes M; Chrysanthaki T; Hendriks J; Wittenberg R; Knapp M; Black N; Smith S
    Int J Geriatr Psychiatry; 2018 Jan; 33(1):5-13. PubMed ID: 28004429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring the cost-effectiveness of a one-off screen for dementia (for people aged 75 years in England and Wales).
    Dixon J; Ferdinand M; D'Amico F; Knapp M
    Int J Geriatr Psychiatry; 2015 May; 30(5):446-52. PubMed ID: 25043227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review and economic evaluation of exercise referral schemes in primary care: a short report.
    Campbell F; Holmes M; Everson-Hock E; Davis S; Buckley Woods H; Anokye N; Tappenden P; Kaltenthaler E
    Health Technol Assess; 2015 Jul; 19(60):1-110. PubMed ID: 26222987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of national mandatory screening of all admissions to English National Health Service hospitals for meticillin-resistant Staphylococcus aureus: a mathematical modelling study.
    Robotham JV; Deeny SR; Fuller C; Hopkins S; Cookson B; Stone S
    Lancet Infect Dis; 2016 Mar; 16(3):348-56. PubMed ID: 26616206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia.
    Handels RLH; Wimo A; Dodel R; Kramberger MG; Visser PJ; Molinuevo JL; Verhey FRJ; Winblad B
    J Alzheimers Dis; 2017; 60(4):1477-1487. PubMed ID: 29081416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How Can We Best Screen for Cognitive Impairment in Malaysia? A Pilot of the IDEA Cognitive Screen and Picture-Based Memory Impairment Scale and Comparison of Criterion Validity with the Mini Mental State Examination.
    Rosli R; Tan MP; Gray WK; Subramanian P; Mohd Hairi NN; Chin AV
    Clin Gerontol; 2017; 40(4):249-257. PubMed ID: 28459304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic utility of Montreal Cognitive Assessment in the Fifth Edition of Diagnostic and Statistical Manual of Mental Disorders: major and mild neurocognitive disorders.
    Liew TM; Feng L; Gao Q; Ng TP; Yap P
    J Am Med Dir Assoc; 2015 Feb; 16(2):144-8. PubMed ID: 25282632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The usfulness of the SLUMS test for diagnosis of mild cognitive impairment and dementia.
    Szcześniak D; Rymaszewska J
    Psychiatr Pol; 2016; 50(2):457-72. PubMed ID: 27288688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detecting MCI and dementia in primary care: effectiveness of the MMS, the FAQ and the IQCODE [corrected].
    Cruz-Orduña I; Bellón JM; Torrero P; Aparicio E; Sanz A; Mula N; Marzana G; Begué C; Cabezón D; Olazarán J
    Fam Pract; 2012 Aug; 29(4):401-6. PubMed ID: 22121012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tracking Cognitive Decline in Amnestic Mild Cognitive Impairment and Early-Stage Alzheimer Dementia: Mini-Mental State Examination versus Neuropsychological Battery.
    Kim J; Na HK; Byun J; Shin J; Kim S; Lee BH; Na DL
    Dement Geriatr Cogn Disord; 2017; 44(1-2):105-117. PubMed ID: 28768247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health economic analysis of the integrated cognitive assessment tool to aid dementia diagnosis in the United Kingdom.
    Shore J; Kalafatis C; Stainthorpe A; Modarres MH; Khaligh-Razavi SM
    Front Public Health; 2023; 11():1240901. PubMed ID: 37841740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for dementia in primary care: a review of the use, efficacy and quality of measures.
    Milne A; Culverwell A; Guss R; Tuppen J; Whelton R
    Int Psychogeriatr; 2008 Oct; 20(5):911-26. PubMed ID: 18533066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An evaluation of the additional benefit of population screening for dementia beyond a passive case-finding approach.
    Mate KE; Magin PJ; Brodaty H; Stocks NP; Gunn J; Disler PB; Marley JE; Pond CD
    Int J Geriatr Psychiatry; 2017 Mar; 32(3):316-323. PubMed ID: 26988976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Montreal Cognitive Assessment and Mini-Mental State Examination reliable change indices in healthy older adults.
    Kopecek M; Bezdicek O; Sulc Z; Lukavsky J; Stepankova H
    Int J Geriatr Psychiatry; 2017 Aug; 32(8):868-875. PubMed ID: 27352935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of a non-pharmacological treatment vs. "care as usual" in day care centers for community-dwelling older people with cognitive impairment: results from the German randomized controlled DeTaMAKS-trial.
    Steinbeisser K; Schwarzkopf L; Graessel E; Seidl H
    Eur J Health Econ; 2020 Aug; 21(6):825-844. PubMed ID: 32219623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.